Method of treating metabolic disorders and depression with dopamine receptor agonists
This invention relates to methods and formulations for treating metabolic disorders and depression. In some embodiments, the methods comprise administering a dopamine receptor agonist and an anti-depressant.
1. A method of treating type-2 diabetes and depression comprising administering to a patient in need thereof at different times of day a therapeutically effective combination of a dopamine receptor agonist and a serotonin enhancing agent, wherein the dopamine receptor agonist is administered at a first predetermined time of day in the morning and the serotonin enhancing agent is administered thereafter at a second predetermined time of day in the evening.
2. The method of claim 1 , wherein the first pre-determined time of day is upon waking.
3. The method of claim 2 , wherein the first pre-determined time of day is within 0400 to 1200 hours.
4. The method of claim 1 , wherein the second pre-determined time of day is within 1-2 hours prior to bedtime.
5. The method of claim 4 , wherein the second pre-determined time of day is within 2000 to 2400 hours.
6. The method of claim 1 , wherein the serotonin enhancing agent is administered in a sub-threshold amount.
7. A method of treating depression and reducing the adverse effects of serotonin enhancing agents on type-2 diabetes in a patient which comprises administering to a patient in need thereof a therapeutically effective amount of a dopamine receptor agonist and a serotonin enhancing agent at different times of day, wherein the dopamine receptor agonist is administered at a first predetermined time of day in the morning and the serotonin enhancing anti-depressant agonist is administered thereafter at a second predetermined time of day in the evening.
8. The method of claim 4 , wherein the second pre-determined time of day is 30 minutes before bedtime.
9. The method of claim 1 wherein the dopamine receptor agonist is bromocriptine.
10. The method of claim 1 wherein the dopamine receptor agonist is an ergot related dopamine D2 agonist.
11. The method of claim 7 , wherein the first pre-determined time of day is upon waking.
12. The method of claim 11 , wherein the first pre-determined time of day is within 0400 to 1200 hours.
13. The method of claim 7 , wherein the second pre-determined time of day is within 2000 to 2400 hours.
14. The method of claim 7 , wherein the second pre-determined time of day is within 1-2 hours prior to bedtime.
15. The method of claim 7 , wherein the second pre-determined time of day is 30 minutes before bedtime.
16. The method of claim 7 wherein the dopamine receptor agonist is bromocriptine.
17. The method of claim 7 wherein the dopamine receptor agonist is an ergot related dopamine D2 agonist.